EXEL EXELIXIS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 939767 · Fiscal year ends 01/01
Financial factors as of 2026-10-02 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.1%
TTM net income YoY30.6%
TTM EPS YoY40.3%
Revenue 3-yr CAGR12.1%
Net income 3-yr CAGR112.6%
Margins
Gross margin96.3%
Operating margin40.2%
Net margin35.5%
FCF margin46.5%
EBITDA margin41.3%
Returns
ROE44.3%
ROA33.2%
ROIC (approx.)47.8%
Asset turnover0.94x
Leverage & solvency
Liabilities / assets27.0%
Debt / equity0.00x
Current ratio3.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.33x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-10-02 | 2026Q22026-07-03 | 2026Q12026-04-03 | 2025Q4*2026-01-02 | 2025Q32025-10-03 | 2025Q22025-07-04 | 2025Q12025-04-04 | 2024Q4*2025-01-03 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $658.70M | $628.69M | $610.81M | $598.66M | $597.75M | $568.26M | $555.45M | $566.75M |
| Cost of revenue | $26.23M | $20.66M | $19.95M | $26.48M | $18.57M | $19.47M | $19.17M | $19.96M |
| Gross profit | $632.46M | $608.03M | $590.86M | $572.18M | $579.18M | $548.79M | $536.27M | $546.79M |
| R&D expense | $209.48M | $211.99M | $199.92M | $213.25M | $199.16M | $200.36M | $212.23M | $249.00M |
| SG&A expense | $154.56M | $147.63M | $139.60M | $123.02M | $123.66M | $134.86M | $137.18M | $134.33M |
| Operating income | $268.42M | $248.41M | $251.34M | $235.22M | $236.54M | $213.58M | $186.86M | $163.21M |
| Income tax | $64.69M | $50.63M | $57.22M | $8.16M | $58.84M | $45.57M | $46.07M | $44.91M |
| Net income | $218.09M | $212.05M | $210.47M | $244.53M | $193.58M | $184.85M | $159.62M | $139.86M |
| EBITDA | $275.36M | $255.40M | $258.29M | $242.16M | $243.96M | $220.92M | $194.20M | $170.85M |
| EPS (basic) | 0.88 | 0.85 | 0.81 | — | 0.72 | 0.68 | 0.57 | — |
| EPS (diluted) | 0.85 | 0.82 | 0.79 | — | 0.69 | 0.65 | 0.55 | — |
| Weighted avg. shares (diluted) | 255.75M | 259.68M | 267.32M | — | 278.54M | 284.39M | 288.18M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $304.77M | $281.45M | $226.15M | $482.49M | $376.30M | $164.43M | $183.75M | $217.37M |
| Short-term investments | $587.24M | $557.94M | $551.05M | $576.60M | $612.24M | $626.66M | $847.56M | $893.90M |
| Receivables | $328.47M | $322.21M | $328.95M | $286.92M | $309.73M | $292.35M | $281.64M | $265.44M |
| Inventory | $29.87M | $28.73M | $26.61M | $21.69M | $27.40M | $23.48M | $24.85M | $22.39M |
| Current assets | $1.32B | $1.25B | $1.21B | $1.44B | $1.40B | $1.18B | $1.40B | $1.47B |
| PP&E, net | $87.28M | $92.67M | $95.52M | $98.96M | $104.75M | $110.31M | $115.03M | $119.39M |
| Goodwill | $63.68M | $63.68M | $63.68M | $63.68M | $63.68M | $63.68M | $63.68M | $63.68M |
| Total assets | $2.51B | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B |
| Current liabilities | $411.88M | $361.93M | $370.98M | $405.64M | $373.78M | $336.11M | $399.10M | $403.77M |
| Total liabilities | $679.66M | $650.47M | $657.85M | $683.10M | $662.85M | $644.54M | $706.22M | $703.49M |
| Shareholders' equity | $1.83B | $1.84B | $1.94B | $2.16B | $2.16B | $2.03B | $2.13B | $2.24B |
| Shares outstanding | 244.68M | 248.88M | 253.70M | 262.48M | 268.10M | 270.13M | 275.03M | 281.73M |
| Cash flow statement | ||||||||
| Operating cash flow | $279.96M | $307.74M | $251.84M | $333.51M | $290.32M | $48.99M | $211.44M | $240.26M |
| Capital expenditure | $2.49M | $6.82M | $1.51M | $1.16M | $1.48M | $2.84M | $2.95M | $3.98M |
| Free cash flow | $277.47M | $300.93M | $250.34M | $332.36M | $288.84M | $46.16M | $208.49M | $236.29M |
| Investing cash flow | -$6.71M | $91.43M | -$51.07M | $27.24M | $25.41M | $248.03M | $49.76M | -$93.20M |
| Financing cash flow | -$249.92M | -$343.88M | -$457.11M | -$254.57M | -$103.86M | -$316.34M | -$294.82M | -$188.03M |
| Depreciation & amortization | $6.93M | $6.98M | $6.95M | $6.95M | $7.42M | $7.34M | $7.34M | $7.64M |
| Stock-based compensation | $28.72M | $32.56M | $29.05M | $20.10M | $30.89M | $36.07M | $25.93M | $26.35M |
| Share buybacks | $249.96M | $322.97M | $430.35M | $257.62M | $104.03M | $301.92M | $283.93M | $190.41M |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.